CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis. (July 2017)

• Record Type: Journal Article
• Authors: Pietroboni, Anna M; Schiano di Cola, Francesca; Scarioni, Marta; Fenoglio, Chiara; Spanò, Barbara; Arighi, Andrea; Cioffi, Sara MG; Oldoni, Emanuela; De Riz, Milena A; Basilico, Paola; Calvi, Alberto; Fumagalli, Giorgio G; Triulzi, Fabio; Galimberti, Daniela; Bozzali, Marco; Scarpini, Elio
• Is Part Of: Multiple sclerosis. Volume 23:Number 8(2017)
• Page Start: 1085
• Page End: 1091
• Publication Date: 2017-07
• Subjects: Multiple sclerosis -- neurodegeneration -- biomarker -- beta-amyloid -- tau; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458516674566
• Languages: English
• ISSNs: 1352-4585

Abstract

Background: Neurodegeneration plays a major role in determining disability in multiple sclerosis (MS) patients. Hence, there is increasing need to identify reliable biomarkers, which could serve as prognostic measure of disease progression. Objectives: To assess whether cerebrospinal fluid (CSF) tau and β-amyloid (Aβ) levels were altered in newly diagnosed MS patients and correlated with disability. Moreover, we investigated whether these CSF biomarkers associate with macroscopic brain tissue damage measures. Methods: CSF Aβ and tau levels were determined by enzyme-linked immunosorbent assay in CSF samples from 48 newly diagnosed MS patients, followed-up clinically for 3 years by recording their Expanded Disability Status Scale score at 6-month intervals, and 45 controls. All patients underwent magnetic resonance imaging at baseline and at the end of follow-up to quantify their lesion load (LL). Results: CSF Aβ levels were significantly reduced in patients compared to controls ( p < 0.001). Lower CSF Aβ levels at baseline were a disability predictor at 3-year follow-up ( p = 0.009). CSF tau levels correlated with T2- and T1-LL ( p < 0.001). Conclusion: CSF Aβ reduction is a promising biomarker of neurodegeneration and may predict patients' clinical outcome. Therefore, CSF Aβ should be considered as a potential biomarker of prognostic value.